Pegfilgrastim biosimilar - Intas Pharmaceuticals

Drug Profile

Pegfilgrastim biosimilar - Intas Pharmaceuticals

Alternative Names: INTP 5; Lapelga; Neupeg; Pegasta; Pegylated Apo-Filgrastim; Recombinant pegylated granulocyte colony stimulating factor - Intas Biopharmaceuticals

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intas Biopharmaceuticals
  • Developer Apotex; Intas Biopharmaceuticals
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 16 Mar 2017 No recent reports of development identified - Phase-III for Neutropenia in Czech Republic, Slovakia, Bulgaria, Greece, and Hungary (SC)
  • 15 Mar 2017 Pegfilgrastim biosimilar is still under Preregistration for Neutropenia in USA (SC)
  • 29 Aug 2016 Intas Pharmaceuticals plans phase I study in healthy volunteers in India (CTRI/2016/07/007096)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top